Caris Life Sciences Caris Discovery

Caris Life Sciences has expanded its Caris Discovery platform, a proprietary, multi-omics target discovery engine designed to unlock otherwise inaccessible drug targets in areas of high unmet clinical need.

The firm said the approach relies on what it calls the ADAPT biotargeting system, which deploys an unbiased library of single-strand DNA aptamers that bind to molecular targets in patient tissue samples. Identified targets are then validated and characterized for their disease and biological relevance via gene expression profiling, epitope mapping, functional screening, phenotypic analyses, and in vitro model systems.